Vaxart trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Wouter W. Latour. Vaxart Inc, formerly known as Aviragen Therapeutics Inc is a bio-pharmaceutical company. It is engaged in developing direct-acting antivirals to treat infections that affect a number of patients.
Previous Intraday Performance:
The VXRT shares had a previous change of -1.93% which opened at 0.70 and closed at 0.70. It moved to an intraday high of 0.72 and a low of 0.68.
SeekingAlpha: Vaxart reports Q1 results
Over the last five trading days, VXRT shares returned -4.66% and in the past 30 trading days it returned -21.80%. Over three months, it changed -61.75%. In one year it has changed -86.51% and within that year its 52 week high was 7.60 and its 52 week low was 0.60. VXRT stock is 15.72% above its 52 week low.
Our calculations result in a 200 day moving average of 2.27 and a 50 day moving average of 1.17. Right now, VXRT stock is trading -69.11% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $10.8m with 15.8m shares outstanding and a float of 13.2m shares. Trading volume was 37,608 shares and has experienced an average volume of 756,918 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Vaxart was -2.34 which ended on 31st of December 2018.
The growth of the EPS is critical in understanding the current valuation of Vaxart; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 0.40% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 6.70% of institutional ownership.
The beta was calculated to be 0.37.
Based on last reported financials, the company’s return on equity is -105.89%, return on assets is -49.34%, price-to-sales is 1.38 and price-to-book is 0.89.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result